Lois Mailander
Cardiovascular Disease · Metairie, LANPI 1851375281
Payments from drug & device makers
Across 144 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$413
- Johnson & Johnson$332
- Pfizer$267
- E.r. Squibb & Sons, L.L.C.$155
- Amgen$140
- Sanofi-aventis U.S. LLC$110
- plus $665 from 13 others
What the payments were for
- Food & beverage$2,080100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 29 | $413 |
| Johnson & Johnson | 28 | $332 |
| Pfizer | 26 | $267 |
| E.r. Squibb & Sons, L.L.C. | 9 | $155 |
| Amgen | 9 | $140 |
| Sanofi-aventis U.S. LLC | 7 | $110 |
| Amarin Pharma, Inc. | 6 | $105 |
| Actelion Pharmaceuticals US, Inc. | 4 | $91 |
| Regeneron Healthcare Solutions, Inc. | 5 | $73 |
| Esperion Therapeutics, Inc. | 3 | $66 |
| Boehringer Ingelheim | 4 | $63 |
| Bayer | 3 | $50 |
| Baxter Healthcare | 1 | $49 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $42 |
| AstraZeneca | 2 | $40 |
| Merck | 2 | $33 |
| Atricure, Inc. | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Gilead | 1 | $15 |
How this compares
$2,080 in reported general payments places this provider in the 40th percentile of 281 cardiovascular disease providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 120 | $106,247 |
| XareltoRivaroxaban | 47 | $36,145 |
| Repatha SureclickEvolocumab | 17 | $20,824 |
| EntrestoSacubitril/Valsartan | 14 | $11,908 |
| Metoprolol Succinate | 151 | $2,060 |
| Rosuvastatin Calcium | 117 | $818 |
| Amlodipine Besylate | 96 | $592 |
| Irbesartan | 35 | $557 |
| Atorvastatin Calcium | 74 | $524 |
| Ezetimibe | 41 | $476 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 33 | $425 |
| SotalolSotalol Hcl | 15 | $386 |
| Hydralazine Hcl | 17 | $364 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 14 | $336 |
| Potassium Chloride | 17 | $226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $267 | $106,247120 claims |
| Johnson & JohnsonXarelto | $332 | $36,14547 claims |
| NovartisEntresto | $413 | $11,90814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Metairie
- Thomas GilesMetairie$66K
- Homeyar DinshawMetairie$14K
- Kamran KhoobehiMetairie$13K
- Ghiath MikdadiHammond$5.7M
- Marc BernsteinSlidell$2.1M
- Anil ChhabraShreveport$1.9M
- Dale PresserCovington$1.7M
- William EavesShreveport$1.6M
- Assad MouhaffelWest Monroe$1.4M
- Wenwu ZhangShreveport$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.